SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Goldman Sachs Downgrades Neurocrine Biosciences to Neutral, Announces $135 Price Target

Goldman Sachs analyst Paul Choi downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Buy to Neutral and announces $135 price target.

Benzinga · -
Goldman Sachs analyst Paul Choi downgrades Neurocrine Biosciences (NASDAQ: NBIX) from Buy to Neutral and announces $135 price target.